NEW YORK (GenomeWeb) – A team from Harvard Medical School this week published the details of a novel approach to drug-target screening, combining the genome-editing technology CRISPR and the gene-silencing technology RNAi to identify three genes that appear to be essential to the growth of tumor cells but not normal cells.

According to the researchers, the method offers a number of advantages over conventional RNAi screening, which is limited by incomplete transfection, partial knockdown, and off-target effects, and therefore often requires secondary screening.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.

Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.